Immunocore

Immunocore is a biotechnology company focused on the development of novel T cell receptor therapies to treat cancer, infectious diseases, and autoimmune disorders. Its lead product candidate, Kimmtrak, is approved for metastatic uveal melanoma. Immunocore's technology platform enables the engineering of soluble TCRs that redirect T cells to recognize and kill diseased cells. The company is headquartered in the United Kingdom and has research and development facilities in the United States. Immunocore partners with pharmaceutical companies and academic institutions to advance its pipeline of immunotherapeutic candidates.